doi: 10.1161/01.CIR.0000133187.74800.B9
(Circulation. 2004;109:3122-3131.)
© 2004 American Heart Association, Inc.
Reviews: Current Perspectives |
Cardiovascular Complications of Cancer Therapy
Diagnosis, Pathogenesis, and Management
From the Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, Tex.
Correspondence to Edward T.H. Yeh, MD, Department of Cardiology, Unit 449, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4095. E-mail etyeh{at}mdanderson.org
The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies. The severity of such toxicity depends on many factors such as the molecular site of action, the immediate and cumulative dose, the method of administration, the presence of any underlying cardiac condition, and the demographics of the patient. Moreover, toxicity can be affected by current or previous treatment with other antineoplastic agents. Cardiotoxic effects can occur immediately during administration of the drug, or they may not manifest themselves until months or years after the patient has been treated. In this article we review commonly used chemotherapy agents, including several recently approved medications, for their propensity to cause cardiotoxicity. Further research will be required to more accurately predict which patients are at risk for developing cardiotoxicity. In addition, management plans, as well as strategies to reduce cardiotoxicity, need to be developed.
Key Words: cardiomyopathy • chemotherapy • complications • drugs
This article has been cited by other articles:
 |
|
 |
|
  G. Di Lorenzo, R. Autorino, G. Bruni, G. Carteni, E. Ricevuto, M. Tudini, C. Ficorella, C. Romano, M. Aieta, A. Giordano, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis Ann. Onc., May 27, 2009; (2009) mdp025v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-X. Wang, Q. Li, and P.-F. Li Apoptosis Repressor with Caspase Recruitment Domain Contributes to Chemotherapy Resistance by Abolishing Mitochondrial Fission Mediated by Dynamin-Related Protein-1 Cancer Res., January 15, 2009; 69(2): 492 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations Oncologist, January 1, 2009; 14(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mantovani, C. Madeddu, C. Cadeddu, M. Dessi, A. Piras, E. Massa, R. Serpe, G. Antoni, and G. Mercuro Persistence, Up to 18 Months of Follow-Up, of Epirubicin-Induced Myocardial Dysfunction Detected Early by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers Oncologist, December 1, 2008; 13(12): 1296 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Lenihan and F. J. Esteva Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer Oncologist, December 1, 2008; 13(12): 1224 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H Wu Cardiotoxic drugs: clinical monitoring and decision making Heart, November 1, 2008; 94(11): 1503 - 1509. [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Armenian and S. Bhatia Cardiovascular disease after hematopoietic cell transplantation - lessons learned Haematologica, August 1, 2008; 93(8): 1132 - 1136. [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Perez, M. Koehler, J. Byrne, A. J. Preston, E. Rappold, and M. S. Ewer Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials Mayo Clin. Proc., June 1, 2008; 83(6): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ravel, V. Dubois, J. Quinonero, F. Meyer-Losic, J. Delord, P. Rochaix, C. Nicolazzi, F. Ribes, C. Mazerolles, E. Assouly, et al. Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin Clin. Cancer Res., February 15, 2008; 14(4): 1258 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tanaka, M. Sata, T. Natori, J.-r. Kim-Kaneyama, K. Nose, M. Shibanuma, Y. Hirata, and R. Nagai Circulating progenitor cells contribute to neointimal formation in nonirradiated chimeric mice FASEB J, February 1, 2008; 22(2): 428 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Z. Li, D.-Y. Lu, W.-Q. Tan, J.-X. Wang, and P.-F. Li p53 Initiates Apoptosis by Transcriptionally Targeting the Antiapoptotic Protein ARC Mol. Cell. Biol., January 15, 2008; 28(2): 564 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R.J. H. Bird and S. M. Swain Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Jones, M. Haykowsky, C. J. Peddle, A. A. Joy, E. N. Pituskin, L. M. Tkachuk, K. S. Courneya, D. J. Slamon, and J. R. Mackey Cardiovascular Risk Profile of Patients with HER2/neu-Positive Breast Cancer Treated with Anthracycline-Taxane-Containing Adjuvant Chemotherapy and/or Trastuzumab Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 1026 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, G. Martinelli, F. Veglia, C. Fiorentini, and C. M. Cipolla Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition Circulation, December 5, 2006; 114(23): 2474 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Moser, E. M. Noordijk, F. E. van Leeuwen, S. le Cessie, J. W. Baars, J. Thomas, P. Carde, J. H. Meerwaldt, M. van Glabbeke, and H. C. Kluin-Nelemans Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma Blood, April 1, 2006; 107(7): 2912 - 2919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aviles, N. Neri, and M. J. Nambo Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy Ann. Onc., February 1, 2006; 17(2): 286 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Ewer, M. T. Vooletich, J.-B. Durand, M. L. Woods, J. R. Davis, V. Valero, and D. J. Lenihan Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment J. Clin. Oncol., November 1, 2005; 23(31): 7820 - 7826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. A. Shmist, R. Kamburg, G. Ophir, A. Kozak, V. Shneyvays, Y. J. Appelbaum, and A. Shainberg N,N,N',N'-Tetrakis(2-pyridylmethyl)-ethylenediamine Improves Myocardial Protection against Ischemia by Modulation of Intracellular Ca2+ Homeostasis J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1046 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Ewer and S. M. Lippman Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity J. Clin. Oncol., May 1, 2005; 23(13): 2900 - 2902. [Full Text] [PDF]
|
|